Screener
Vera Therapeutics VERA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $13,909 | $21,898 |
| Accrued expenses and other liabilities, current | 31,240 | 31,557 |
| Total current liabilities | 45,149 | 53,455 |
| Long-term debt | 75,029 | 74,838 |
| Other liabilities, noncurrent | 1,864 | 1,919 |
| Total liabilities | 122,042 | 130,212 |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's accrued expenses?
- Vera Therapeutics (VERA) reported accrued expenses of $31.24M in Q1 2026.
- How has Vera Therapeutics's accrued expenses changed year-over-year?
- Vera Therapeutics's accrued expenses increased by 1046.0% year-over-year, from $2.73M to $31.24M.
- What is the long-term trend for Vera Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Vera Therapeutics's accrued expenses has grown at a 126.0% compound annual growth rate (CAGR), from $535K to $31.56M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Vera Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude